GlobeNewswire: Immunomedics, Inc. Contains the last 10 of 555 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T09:57:41ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/10/12/2106793/0/en/Immunomedics-Announces-FDA-Orphan-Drug-Designation-of-Trodelvy-for-Adult-and-Pediatric-Glioblastoma.html?f=22&fvtc=4&fvtv=6226Immunomedics Announces FDA Orphan Drug Designation of Trodelvy™ for Adult and Pediatric Glioblastoma2020-10-12T12:00:00Z<![CDATA[MORRIS PLAINS, N.J., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted Trodelvy (sacituzumab govitecan-hziy) orphan status for the treatment of adult and pediatric patients with glioblastoma.]]>https://www.globenewswire.com/news-release/2020/09/19/2096162/0/en/Immunomedics-Announces-Positive-Results-from-Pivotal-Phase-2-TROPHY-U-01-Study-of-Trodelvy-in-Metastatic-Urothelial-Cancer.html?f=22&fvtc=4&fvtv=6226Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy™ in Metastatic Urothelial Cancer2020-09-19T15:00:00Z<![CDATA[Trodelvy achieves a 27 percent overall response rate and a 5.9-month median duration of response in heavily-pretreated patients with metastatic urothelial cancer (mUC)]]>https://www.globenewswire.com/news-release/2020/09/19/2096160/0/en/Trodelvy-Significantly-Extends-Survival-in-Phase-3-ASCENT-Study-of-Metastatic-Triple-Negative-Breast-Cancer.html?f=22&fvtc=4&fvtv=6226Trodelvy™ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer2020-09-19T14:30:00Z<![CDATA[Trodelvy significantly reduced the risk of death by 52 percent, with a median overall survival (OS) of 12.1 months compared to 6.7 months for standard single-agent chemotherapy]]>https://www.globenewswire.com/news-release/2020/09/18/2095804/0/en/Immunomedics-Announces-Encouraging-Early-Stage-Clinical-Results-with-Trodelvy-in-Brain-Cancers.html?f=22&fvtc=4&fvtv=6226Immunomedics Announces Encouraging Early-Stage Clinical Results with Trodelvy™ in Brain Cancers2020-09-18T12:00:00Z<![CDATA[Results include partial responses in small cohort of patients with brain metastasis from breast cancer (BMBC) and recurrent glioblastoma (rGBM) Results include partial responses in small cohort of patients with brain metastasis from breast cancer (BMBC) and recurrent glioblastoma (rGBM)]]>https://www.globenewswire.com/news-release/2020/09/09/2090740/0/en/Immunomedics-Announces-Key-Oral-Presentations-at-ESMO-Virtual-Congress-2020.html?f=22&fvtc=4&fvtv=6226Immunomedics Announces Key Oral Presentations at ESMO Virtual Congress 20202020-09-09T11:00:00Z<![CDATA[Breadth of presentations include i) Full results from ASCENT; ii) Final results from TROPHY U-01 cohort 1; iii) First results with Trodelvy™ in brain tumors]]>https://www.globenewswire.com/news-release/2020/09/02/2087646/0/en/Immunomedics-to-Participate-in-Upcoming-Healthcare-Conferences.html?f=22&fvtc=4&fvtv=6226Immunomedics to Participate in Upcoming Healthcare Conferences2020-09-02T12:00:00Z<![CDATA[MORRIS PLAINS, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that Dr. Behzad Aghazadeh, Executive Chairman, is scheduled to participate in virtual fireside chats at the following healthcare conferences:]]>https://www.globenewswire.com/news-release/2020/08/17/2079188/0/en/Immunomedics-Announces-FDA-Approval-of-Samsung-Biologics-as-Antibody-Manufacturer-for-Trodelvy.html?f=22&fvtc=4&fvtv=6226Immunomedics Announces FDA Approval of Samsung Biologics as Antibody Manufacturer for Trodelvy™2020-08-17T12:00:00Z<![CDATA[Approval enhances long-term supply of Trodelvy Approval enhances long-term supply of Trodelvy]]>https://www.globenewswire.com/news-release/2020/08/05/2073573/0/en/Immunomedics-Reports-Second-Quarter-2020-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=6226Immunomedics Reports Second Quarter 2020 Results and Provides Corporate Update2020-08-05T20:00:00Z<![CDATA[Encouraging early adoption of Trodelvy™ in U.S. with $20.1M net sales in first two months of launch]]>https://www.globenewswire.com/news-release/2020/07/27/2067876/0/en/Immunomedics-to-Report-Second-Quarter-2020-Results-and-Host-Conference-Call-and-Webcast-on-August-5-2020.html?f=22&fvtc=4&fvtv=6226Immunomedics to Report Second Quarter 2020 Results and Host Conference Call and Webcast on August 5, 20202020-07-27T12:00:00Z<![CDATA[MORRIS PLAINS, N.J., July 27, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that it will host a conference call on Wednesday, August 5, 2020 at 5:00 p.m. Eastern Time to discuss financial results for the second quarter of 2020 and provide a corporate update.]]>https://www.globenewswire.com/news-release/2020/07/13/2061470/0/en/Immunomedics-Expands-Collaboration-with-Roche-Evaluating-Trodelvy-sacituzumab-govitecan-hziy-in-Combination-with-Tecentriq-atezolizumab-into-Urothelial-and-Non-Small-Cell-Lung-Canc.html?f=22&fvtc=4&fvtv=6226Immunomedics Expands Collaboration with Roche Evaluating Trodelvy™ (sacituzumab govitecan-hziy) in Combination with Tecentriq® (atezolizumab) into Urothelial and Non-Small Cell Lung Cancers2020-07-13T20:00:00Z<![CDATA[Companies have ongoing collaboration in first-line metastatic triple-negative breast cancer]]>